Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

Research output: Contribution to journalArticle


In the present report, we address the question if the reduction of standard dosage of imatinib mesylate (IM) in imatinib-intolerant chronic myeloid leukemia (CML) patients with undetectable residual disease may impair their outcome. Four patients are described. The median follow up from the beginning of IM therapy was 35 months (33-59). The median duration of real-time quantitative polymerase chain reaction (RQ-PCR) negativity on IM 200 mg daily was 17months (4-37). We hypothesize that in IM intolerant CML patients with complete molecular remission, the compound dosage might be safely reduced to a lower than standard dose without to lose the response. A tight molecular monitoring of such patients should be required.

Original languageEnglish
Pages (from-to)749-752
Number of pages4
JournalAnnals of Hematology
Issue number10
Publication statusPublished - Oct 2007



  • CML
  • Drug intolerance
  • Drug resistance
  • Imatinib mesylate
  • Molecular remission
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology

Cite this